HomeHome>Lingang Life Science

OBiO Technology opens precision medical base in Lin-gang

en.lingang.gov.cn| Updated: Apr 25, 2023 L M S

A listed company – engaged in the research and development and production of recombinant viruses for gene therapy – recently opened a precision medical industry center in the Lin-gang Special Area in East China's Shanghai.

OBiO Technology (Shanghai) Corp Ltd – specializing in basic life sciences research, gene therapy drug incubation and clinical-grade recombinant viruses – started operating the facility on April 21.

The center cost about 1.5 billion yuan ($217.4 million), with a total floor space of about 77,000 square meters. With the largest reactor containing 2,000 liters, it is said to be currently the world's only commercial production service base for single gene cell therapy.

It will provide one-stop CRO/CDMO – Contract Research Organization / Contract Development and Manufacturing Organization – solutions from DNA to NDA for the global gene and cell therapy industry.

This is understood to better meet the rapidly growing CDMO demand for gene therapy and will boost the industry supply chain.

As one of the earliest companies in the layout of cell and gene therapy (CGT) research and development outsourcing platform services, OBiO Technology is said to have consolidated its competitive advantage in the field over a number of years.

Furthermore, the company's precision medical industry base has more than 30 gene and cell therapy production lines, with the capacity for large-scale multiple selection of prokaryotic cells production.

In terms of ultra-new process innovation, it has a disposable process vector production line, a disposable process prokaryotic cell cultivation production line, a freeze-drying and an integrated innovative filling system, as well as a positive sample cell therapy product production line. The innovation level is said to be at the forefront of its field.

The completion of the new center is seen as being a major step forwards for OBiO Technology to actively expand its production capacity.

As a result, the company will have the largest good manufacturing practice (GMP) production capacity in China and be at the forefront in this area globally.

In addition, the new production line covers almost all global mainstream CGT production systems and process systems, some of which are domestically pioneering systems. It also introduces a highly automated production system to create comprehensive intelligent output.


An opening ceremony is held on April 21 for OBiO Technology's precision medical industry center in the Lin-gang Special Area. [Photo/WeChat ID: shlgguanweihui]